Finding a single "European medical article" that acts as a definitive source for Deep TMS treatment for autism can be challenging, as research is ongoing and often published in international journals, not solely "European" ones.
However, a highly relevant article that is published in a European journal and discusses Deep TMS for Autism is https://www.cambridge.org/core/journals/european-psychiatry/article/abs/deep-transcranial-magnetic-stimulation-as-a-treatment-for-psychiatric-disorders-a-comprehensive-review/E2683579C8A5C5495BD1D4425A3978B6
Important Note for use:
While this review mentions Autism, remember that the CE Mark approval for Autism specifically came later (as mentioned by BrainsWay).
This article would serve as a good foundational scientific paper discussing the potential and mechanisms of Deep TMS for Autism within a European academic context, rather than being the direct document of CE approval itself.
For the most up-to-date and specific clinical trial data, you would often need to look for more recent individual studies, which may or may not be exclusively published in European journals but are often international collaborations.
Clinical studies and research in Europe indicate that symptoms can improve with age and various interventions.
There is currently no known cure for ASD.
Here's what the available information suggests regarding improvements and outcomes in Europe:
Symptom Improvement with Interventions. Therapies and behavioral interventions are designed to address specific symptoms and can lead to substantial improvement in individuals with ASD.
For instance, studies have shown improvements in areas such as communication, social interaction, cognition, and management of repetitive behaviors with certain treatments like deep repetitive transcranial magnetic stimulation and other interventions.
No "Cure" or Standard Remission Rates. Research consistently states that there is no cure for ASD. Therefore, "remission rates" in the sense of complete disappearance of the condition are not typically reported in clinical literature. The focus is more on improving quality of life and functional skills.
Prevalence vs. Remission Most European studies provide data on the prevalence of Autism (how many people have it) rather than remission. Prevalence rates vary across European countries due to differences in diagnostic criteria, awareness, and healthcare access.
For example, the estimated prevalence rate of ASD in Europe is approximately 59 per 10,000 people, with significant variations (e.g., UK at 700.07 per 100,000 children, France at 69.3 per 10,000, and Iceland at 1 in 100 individuals). These figures reflect the diagnosis of ASD, not its remission.
In summary, while there aren't clinically proven numbers for "Autism remission" in Europe, various interventions aim to mitigate difficulties and enhance skills, leading to significant symptom improvement for many individuals.
References
Autism in Europe - Mastermind Behavior Services
Some elements about the prevalence of Autism Spectrum Disorders (ASD) in the European Union